Pharmacists Endorse H.R. 2375 to Preserve Seniors' Access to Diabetes Testing Supplies and Other Durable Medical Equipment

Published Online: Thursday, June 20, 2013
Follow Pharmacy_Times:

June 20, 2013 (Alexandria, Va.) - With the July 1 scheduled implementation of Medicare's so-called "competitive bidding" and National Mail Order program for diabetes test supplies (DTS) fast approaching, the National Community Pharmacists Association (NCPA) is urging lawmakers to support H.R. 2375, recently introduced legislation that would delay the programs until a number of issues can be resolved. H.R. 2375, the Transparency and Accountability in Medicare Bidding Act, was introduced by U.S. Rep. Glenn "G.T." Thompson (R-Penn.) and Bruce Braley (D-Iowa), and is co-sponsored by Reps. Lou Barletta (R-Penn.), Bill Posey (R-Fla.), Tom Rooney (R-Fla.), Ileana Ros-Lehtinen (R-Fla.), and C.A. "Dutch" Ruppersberger (D-Md.).

"This legislation is in the best interests of patients, which is why NCPA enthusiastically supports its enactment," said NCPA CEO B. Douglas Hoey, RPh, MBA. "The National Mail Order program policies Medicare is implementing are penny-wise and pound-foolish because they run the significant risk of contributing to more hospitalizations and costly health care interventions for diabetes patients. In addition, by steering patients away from their longtime community pharmacist, Medicare's changes fly in the face of bipartisan efforts toward better coordinated care models, such as through medical homes and accountable care organizations."

The Centers for Medicare & Medicaid Services (CMS) is preparing to implement cuts that will collectively represent a 72 percent reduction this year in pharmacy reimbursement for diabetes testing supplies. Such unsustainable reductions may force some community pharmacies to stop offering DTS to seniors, which could create access concerns in underserved rural and inner-city areas. In addition, it will force some seniors to switch from higher-quality glucose meters to lower-end models.

Moreover, CMS is imposing a senseless ban on same-day, home deliveries by independent community pharmacists to homebound seniors and beneficiaries in assisted living facilities. Starting July 1, Medicare will pay the same amount whether patients access their diabetes testing supplies face-to-face from a local health care provider or through the mail, but the agency's new definition of "mail order" would prohibit community pharmacies from continuing to provide delivery services.

"Many seniors may experience some disruption as both the providers and the equipment to which they are accustomed may no longer be available to them," Hoey added. "Some beneficiaries have relied on their community pharmacy for decades. There's no justification for banning these trusted providers from furnishing this service to some of Medicare's frailest populations—beneficiaries who are homebound or in assisted living facilities—at no added cost to the government."

Recently 43 members of Congress led by U.S. Reps. Aaron Schock (R-Ill.) and Peter Welch (D-Vt.) wrote to Medicare to question the prohibition on such deliveries. The new policy "will cause disruption in the care provided to Medicare patients," the lawmakers wrote. "Now that retail and mail order suppliers receive the same level of reimbursements, we believe there is no further reason to prohibit home delivery by retail pharmacies. We ask that you expeditiously consider allowing small retail pharmacies to continue home delivery and not prevent these crucial face-to-face counseling and adherence services from being available to Medicare patients."

Related Articles
The FDA announced today that it will permit the marketing of a mobile medical app that will help patients with diabetes share data from a continuous glucose monitor with other individuals.
Leaders of Senate and House committees with health care jurisdiction should hold oversight hearings to examine the issues that plagued approximately 50,000 beneficiaries who are covered by Aetna Medicare Part D drug plans.
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
The introduction of sodium glucose transporter 2 inhibitors has marked a turning point in the management of patients with both type 1 and type 2 diabetes.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times